News
Nadav Ahituv, PhD
Tue Feb 4, 2025
Department of Bioengineering and Therapeutic Sciences professor Nadav Ahituv is part of a team of researchers using the gene editing technology CRISPR to deprive tumors of nutrition.
Mon Dec 30, 2024
Here are some of the standout moments from 2024 that drove our commitment to leadership in research, education, patient care, and innovation, all aimed at expanding knowledge and enhancing health worldwide.
Fri Dec 6, 2024
The recognition of Krogan, Shoichet, Manglik, and Giacomini underscores the school’s commitment to fostering groundbreaking research that addresses critical issues in health care and pharmaceutical sciences.
Tue Nov 5, 2024
The first program of its kind in the United States, the MS in AICD3 is enabling its graduates to gain a competitive edge for some of the most desirable jobs in the biopharmaceutical industry and in academia.
Thu Oct 24, 2024
The Department of Bioengineering and Therapeutic Sciences (BTS) chair is leading a multidisciplinary team that will receive federal funding to prevent side effects before drugs go to clinical trials.
Tue Aug 6, 2024
The director of the UCSF Institute for Human Genetics (IHG) is being recognized for his lab’s work investigating gene regulatory elements––their relationship to human diversity and disease and their utilization for gene therapy.
Mon Jul 8, 2024
June 14, 2024, marked the 15-year collaboration of a Chinese course improving medical product development and regulation.
Tue May 21, 2024
The pioneering career of one of the School’s most influential faculty members was honored on his 87th birthday.
Tue Apr 30, 2024
Bhushan Kharbikar, PhD, a postdoctoral fellow in the laboratories of Professors Qizhi Tang, PhD, and Tejal Desai, PhD, has been awarded a prestigious JDRF Advanced Postdoctoral Fellowship. JDRF is the leading global organization funding type 1 diabetes (T1D) research. This JDRF fellowship is designed to attract qualified and promising...
Mon Apr 1, 2024
The Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium has been awarded a $30.8M grant over five years to research the most effective treatment options for future clinical testing.
- Page 1
- ››